Provided by Tiger Trade Technology Pte. Ltd.

Prometheus Biosciences, Inc.

199.92
0.0000
Volume:- -
Turnover:371.96M
Market Cap:9.56B
PE:-56.74
High:199.92
Open:199.92
Low:199.92
Close:199.92
52wk High:199.98
52wk Low:22.31
Shares:47.81M
Float Shares:33.23M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5235
EPS(LYR):-3.4899
ROE:-33.30%
ROA:-20.06%
PB:13.70
PE(LYR):-57.28

Loading ...

Company Profile

Company Name:
Prometheus Biosciences, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Ignyta, Inc., a precision oncology biotechnology company, engages in discovering, in-licensing or acquiring, developing, and commercializing molecularly targeted therapies for eradicating residual diseases. Its products pipeline includes entrectinib, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors, ROS1, and ALK proteins, which is in Phase II and two Phase I clinical studies in molecularly defined adult patient populations for the treatment of solid tumors, as well as in Phase I/Ib clinical study in pediatric patients with advanced solid tumor malignancies; RXDX-105, a multikinase inhibitor targets as RET and BRAF that is in Phase I/Ib dose escalation clinical trial; and RXDX-106, a pseudo-irreversible inhibitor, which is in late preclinical development. The company was founded in 2011 and is headquartered in San Diego, California.